Skip to main content
Evidence Snapshot

Protein kinase C delta type

CHEMBL2996 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2996
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C delta type as ChEMBL target CHEMBL2996, mapped to UniProt Q05655. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C delta type
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2996
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q05655
Protein kinase C delta type
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Protein kinase C delta type matters

As of 2026-09-13

Protein kinase C delta type is reviewed as Protein kinase C delta type (UniProt Q05655); Protein kinase C delta type shows clinical signal disease relevance led by myocardial infarction.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 2413 compounds, and 502 assays, with lead potency reaching pChEMBL 10.0.

Disease context
myocardial infarction

Protein kinase C delta type shows clinical signal disease relevance led by myocardial infarction. 1 linked drug keep the rationale reviewable. Linked drugs include DELCASERTIB.

Start review with myocardial infarction because it currently carries clinical signal support. Linked drugs include DELCASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 8 approved drugs, 2413 compounds, and 502 assays for this target. The dominant activity type is KI. CHEMBL2151411 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL2151411 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine
8 approved pChEMBL 10.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Protein kinase C delta type matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q05655, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why myocardial infarction is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2413
Total Compounds
502
Total Assays
8
Approved Drugs
IC50: 713.0, KI: 1005.0, EC50: 79.0, KD: 378.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2151411
 10.0 IC50 —
No preferred name
CHEMBL5172923
 10.0 Ki —
No preferred name
CHEMBL5653589
 9.9 Kd —
No preferred name
CHEMBL388978
 9.9 IC50 —
No preferred name
CHEMBL27768
 9.7 Kd —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
ABEMACICLIB
CHEMBL3301610
 2017
INGENOL MEBUTATE
CHEMBL1863513
 2010
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:18Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2996